SNS-032

SNS-032 (also known as BMS-387032) is a synthetic small-molecule inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK2, CDK7, and CDK9. These kinases are critical regulators of cell cycle progression and transcription. By inhibiting these targets, SNS-032 induces cell cycle arrest at the G2/M phase and promotes apoptosis in cancer cells. The drug has demonstrated potent cytotoxicity against various cancer cell lines in vitro and was investigated for use in hematologic malignancies such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). Its mechanism involves inhibition of phosphorylation of RNA polymerase II, leading to decreased expression of antiapoptotic proteins like Mcl-1 and XIAP. Despite promising preclinical activity, clinical development was discontinued after early-phase trials due to limited efficacy[1][2][3][6][7].

Other names

cdk inhibitor sns-032